FORM OF AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 16, 2026, BY AND BETWEEN ADIAL PHARMACEUTICALS, INC. AND THE INVESTOR SIGNATORIES THERETO
ADIAL PHARMACEUTICALS, INC.
AMENDMENT NO. 2
TO
SECURITIES PURCHASE AGREEMENT
This Amendment No. 2 to Securities Purchase Agreement (this “Amendment”) is entered into as of September 16, 2026, by and among Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on the signature pages hereto (each, an “Investor” and together, the “Investors”).
RECITALS
** **
WHEREAS, the Company and each of the Persons listed on Exhibit A attached thereto entered into that certain Securities Purchase Agreement, dated as of June 11, 2026, as amended on August 12, 2026 (the “Agreement”);
** **
WHEREAS, Section 8.16 of the Agreement provides that no amendment, modification, alteration, waiver or change in any of the terms of the Agreement shall be valid or binding unless made in writing and duly executed by the Company and a Majority in Interest of the Investors;
** **
…